Skip to main content

Overview

All information and news about Medincell stock (Euronext Paris: MEDCL)

Medincell share price

28.26€

-0.42 / -1.46%

2025-11-21 17:38 (Paris)

Data provided by Euronext, in real time.

See stock quote, chart & historical on Euronext.com

Listed on

Euronext Paris /
B Compartment

ISIN code / Ticker

FR0004065605 /
MEDCL

Number of shares

33,098,886
(September 30, 2025)

Liquidity Provider

Rothschild Martin Maurel

Analyst coverage

Medincell is followed by the analysts listed. Please note that any opinions, estimates, or forecasts regarding Medincell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Medincell or its management. Medincell does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions, or recommendations.

Company

Analyst

Contact

Evercore

Michael DiFiore

Truist Securities

Les Sulewski

H.C. Wainwright & Co.

Raghuram Selvaraju

Jefferies

Shan Hama

Stifel

Oscar Haffen Lamm

ODDO BHF

Martial Descoutures

Kepler Chevreux

Nicolas Pauillac

Portzamparc

Mohamed Kaabouni

TP ICAP

Claire Deray

Documentation

November 2025

Corporate presentation

2025

CSR report

Latest news

[Replay] Jefferies Global Healthcare Conference 2025
November 13, 2025

[Replay] Jefferies Global Healthcare Conference 2025

Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
November 11, 2025

Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth

Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
November 10, 2025

Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark

Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)
November 6, 2025

Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)

UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
November 5, 2025

UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025

Investors contacts

Medincell

David Heuzé

Head of Corporate and Financial Communications, and ESG

Medincell

Grace Kim

Head of US Financial Strategy & IR

Investor relations

Louis-Victor Delouvrier
& Alban Dufumier

Newcap

Media

Nicolas Merigeau

Newcap